Search
Caribou Biosciences Inc
CRBUAdd to Watchlist
1.820USD
+0.060+3.41%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
176.45MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.41%
5 Days
+8.33%
1 Month
-11.86%
6 Months
+14.47%
Year to Date
+14.47%
1 Year
+32.85%
Key Figures
1.770Open
1.920High
1.87MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.93%Turnover Ratio
1.760Prev. Close
1.770Low
2.27MTurnover
LossP/E Static
1.73P/B
0.00%Div Yield TTM
-63.04%ROA
3.53552wk High
0.73Volume Ratio
-149.10MNet Profit
96.95MShares
-1.4163EPS TTM
2.32Beta
-83.46%ROE
0.95752wk Low
8.52%Amplitude
100.00%Gross Margin
176.45MMarket Cap
-2.83Reward/Risk
5.23%Risk Rate
TradingKey Stock Score of Caribou Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Caribou Biosciences Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 159 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.12.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Caribou Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Caribou Biosciences Inc Highlights
StrengthsRisks
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 11.16M.
Fairly Valued
The company’s latest PE is -1.29, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.96M shares, decreasing 40.06% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 545.45K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.125
Target Price
+588.92%
Upside Space
Caribou Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Caribou Biosciences Inc Info
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Ticker SymbolCRBU
CompanyCaribou Biosciences Inc
CEOHaurwitz (Rachel E)
Websitehttps://www.cariboubio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Caribou Biosciences Inc (CRBU)?
The current price of Caribou Biosciences Inc (CRBU) is 1.82.
What is the symbol of Caribou Biosciences Inc?
The ticker symbol of Caribou Biosciences Inc is CRBU.
What is the 52-week high of Caribou Biosciences Inc?
The 52-week high of Caribou Biosciences Inc is 3.54.
What is the 52-week low of Caribou Biosciences Inc?
The 52-week low of Caribou Biosciences Inc is 0.96.
What is the market capitalization of Caribou Biosciences Inc?
The market capitalization of Caribou Biosciences Inc is 176.45M.
Is Caribou Biosciences Inc (CRBU) currently rated as Buy, Hold, or Sell?
According to analysts, Caribou Biosciences Inc (CRBU) has an overall rating of Buy, with a price target of 12.12.
What is the Earnings Per Share (EPS TTM) of Caribou Biosciences Inc (CRBU)?
The Earnings Per Share (EPS TTM) of Caribou Biosciences Inc (CRBU) is -1.59.